Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

PHASE2CompletedINTERVENTIONAL
Enrollment

482

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 5, 2017

Study Completion Date

May 5, 2017

Conditions
Alzheimer's Disease
Interventions
DRUG

T-817MA-H

224 mg or 448 mg T-817 MA once daily

DRUG

T-817MA-L

224 mg T-817 MA once daily

DRUG

Placebo

Placebo

Trial Locations (50)

Unknown

Banner Alzheimer's Institute, Phoenix

Banner Sun Health Research Institute, Sun City

University of Arizona Health Sciences Center, Tucson

Neurology Center of North Orange County, Fullerton

UCSD Comprehensive Alzheimer's Program, La Jolla

UC Irvine Medical Center, Orange

Geriatric and Adult Psychiatry, LCC, Hamden

Yale University, Alzheimer's Disease Research Unit, New Haven

Research Center for Clinical Studies, Inc., Norwalk

Georgetown University Clinical Research Unit, Washington D.C.

Infinity Clinical Research, LLC, Hollywood

University of Miami Miller-School of Medicine, Miami

Scientific Clinical Research, Inc, North Miami

Renstar Medical Research, Ocala

Meridien Research, Tampa

Neuro Trials Research, Inc, Atlanta

Rush University Medical Center, Chicago

SIU School of Medicine, Springfield

Indiana Medical Research, Elkhart

Indiana University Health Partners, Adult Neurology Clinic, Indianapolis

University of Iowa Hospitals and Clinics, Iowa City

University of Kansas/Clinical and Translational Science Unit, Fairway

University of Kentucky Sanders-Brown Center on Aging Clinic, Lexington

Pennington Biomedical Research Center, Baton Rouge

Acadia Hospital, Bangor

Boston University Alzheimer's Disease Center, Boston

University of Michigan Health System/ Michigan Clinical Research Unit, Ann Arbor

Michigan State University, East Lansing

Bronson Neurobehvioral Health, Paw Paw

University of Nebraska Medical Center(Geri Psych), Omaha

Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas

Global Medical Institutes, LLC;Princeton Medical Institute, Princeton

Dent Neurologic Institute, Amherst

Alzheimer's Disease Research Center of Mount Sinai, New York

Columbia University Medical Center Sergievsky Center Taub Institute, New York

The Nathan S. Kline Instituite for Psychiatric Research, Orangeburg

University of Rochester Medical Center, Rochester

SUNY Upstate Medical University, Syracuse

Wake Forest University (WFU) School of Medicine, Winston-Salem

Case Western Reserve University/ University Hospitals Case Medical Center, Beachwood

Tulsa Clinical Research, LLC, Tulsa

Hospital at the University of Pennsylvania, Penn Memory Center, Philadelphia

University of Pittsburgh, Alzheimer Disease Research Center, Pittsburgh

Abington Neurological Associates, LTD., Willow Grove

Roper St. Francis Healthcare, Charleston

Vanderbilt University Medical Center -VUIIS, Nashville

University of North Texas Health Science Center, Fort Worth

Houston Methodist Hospital, Houston

University of Wisconsin Hospital and Clinics, Madison

Cary J. Kohlenberg MD., SC dba IPC Research, Waukesha

All Listed Sponsors
collaborator

Alzheimer's Disease Cooperative Study (ADCS)

OTHER

lead

FUJIFILM Toyama Chemical Co., Ltd.

INDUSTRY

NCT02079909 - Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202) | Biotech Hunter | Biotech Hunter